Related Experiment Video
Updated: Oct 6, 2025

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
Published on: June 18, 2013
Tumor-Targeting Peptide for Redox-Responsive Pt Prodrug and Gene Codelivery and Synergistic Cancer Chemotherapy
Yaxuan Bai1, Zeyu Li1, Liping Liu2
1Department of Chemistry, College of Science, Northeast Forestry University, 26 Hexing Road, Harbin 150040, China.
Abstract:
A new codelivery system combining prodrug strategy, siRNA/BAplatin @CRGDK NPs, to overcome cisplatin (CDDP) resistance in human breast cancer was designed and researched. Negatively charged siRNA was deposited onto the surface of tumor-targeting peptide-functionalized BAplatin@CRGDK NPs. SiRNA/BAplatin@CRGDK NPs could facilitate cellular uptake of BAplatin and increase the cell proliferation suppression effect of Pt against MDA-MB-231/DDP cells. The tumor-to-kidney uptake ratio of the siRNA/BAplatin@CRGDK NPs in MB-231/DDP tumors is 2.4-fold higher than that of cisplatin in MB-231/DDP tumors, thus giving rise to more significant antitumor efficacy. It demonstrated that the siRNA/BAplatin@CRGDK NPs is a potential, safe, and efficient therapeutic agent for cancer therapy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy

